

Equianalgesic Dosing of Opioids for Pain Management

Equianalgesic doses contained in this chart are approximate, and should be used only as a guideline. Dosing must be titrated to individual response. There is often incomplete cross-tolerance among these drugs. **It is, therefore, recommended to begin with a 50% lower dose than the equianalgesic dose when changing drugs and then titrate to a safe/effective response.**^{1,3,4,34} Dosing adjustments for renal or hepatic insufficiency, cytochrome P450 drug interactions, genetics, and other conditions or medications that affect drug metabolism, kinetics, or response may also be necessary.^{2,34,48,53} Also consider pain control at time of switch.^{4,5} In general, use cautious dosing for elderly or debilitated patients, and patients with renal or hepatic impairment.⁴⁸ Some products have specific dosing recommendations for these populations (see footnotes). See our Opioid Conversion Algorithm for instructions on converting from one opioid to another.

A website with an equianalgesic dose calculator is available at <http://www.hopweb.org>

Drug ^{f,i,k,L}	Equianalgesic Doses (mg) ^{1,3,4}		Approximate Equianalgesic 24 hr Dose (Assumes Around-the-Clock Dosing) ⁸		Usual Starting Dose (Opioid-Naïve Adults) (Doses NOT Equianalgesic)	
	Parenteral	Oral	Parenteral	Oral/Other	Parenteral	Oral/Other
Morphine (immediate-release tablets, oral solution) ^{k,L}	10	30	3-4 mg q 4 h	10 mg q 4 h	2.5 mg q 4 h ⁵⁰	10 mg q 4 h (acute or chronic pain) ^{40,41,51,j} 2-10 mg q 4 h (hospice) ⁵
Controlled-release morphine (e.g., <i>MS Contin</i> , <i>Kadian</i>)	NA	30	NA	30 mg q 12 h (<i>Kadian</i> may be given as 60 mg q 24 h) ^{6,21}	NA	Not for initial dosing. ^{6,21,29,h,j}
Extended-release morphine (<i>Avinza</i> [U.S.], <i>Embeda</i> [with naltrexone, U.S.]	NA	30	NA	60 mg q 24 h (<i>Embeda</i> may be given as 30 mg q 12 h) ¹²	NA	<i>Avinza</i> : 30 mg q 24 h ^{7,j} <i>Embeda</i> : 20 mg q 24 h ^{12,j}

More . . .

Drug ^{f,i,k,L}	Equianalgesic Doses (mg) ^{1,3,4}		Approximate Equianalgesic 24 hr Dose (Assumes Around-the-Clock Dosing) ^g		Usual Starting Dose (Opioid-Naïve Adults) (Doses NOT Equianalgesic)	
	Parenteral	Oral	Parenteral	Oral/Other	Parenteral	Oral/Other
Hydromorphone (<i>Dilaudid</i>)	1.5-2	7.5-8	0.5-0.8 mg q 4 h	2-4 mg q 4 h	See footnotes a,d.	See footnote a.
Controlled-release hydromorphone (<i>Hydromorph Contin</i> [Canada])	NA	7.5 mg	NA	6 mg q 12 h	NA	3 mg q 12 h ^{30,j}
Extended-release hydromorphone (<i>Exalgo, Jurnista</i> [Canada])	NA	See footnote b.	NA	See footnote b.	NA	See footnotes e, h, and j.
Oxycodone (e.g., <i>Roxicodone</i> [U.S.], <i>Oxecta</i> [U.S.], <i>Oxy IR</i> [Canada], also in <i>Percocet</i> , others)	NA	20-30	NA	5-10 mg q 4 h	NA	5-15 mg q 4-6 h (acute or chronic pain) ^{42,43} (Product labeling) 5-10 mg q 8-12 h ¹⁴ or 5 mg q 4-6 h ⁴¹ (chronic noncancer pain) (Guidelines)
Controlled-release oxycodone (<i>OxyContin</i> [U.S.], <i>OxyNeo</i> [Canada])	NA	20-30	NA	20-30 mg q 12 h	NA	10 mg q 12 h ^{9,j}
Oxymorphone (<i>Opana</i> [U.S.])	1	10	0.3-0.4 mg q 4 h	5 mg q 6 h	0.5 mg q 4-6 h ¹⁰	10-20 mg q 4-6 h (acute pain) ^{44,r} 5-10 mg q 4-12 h (chronic noncancer pain) ^{14,41}
Extended-release oxymorphone (<i>Opana ER</i> [U.S.]) ^{c,q}	NA	10	NA	10 mg q 12 h	NA	5 mg q 12 h ^{11,j}
Hydrocodone (in <i>Lortab</i> [U.S.], <i>Vicodin</i> [U.S.], others)	NA	30-45	NA	10-15 mg q 4 h	NA	5-10 mg q 4-6 h ⁴⁵ 5-10 mg q 4-12 h (chronic noncancer pain) ^{14,41}

Drug ^{f,i,k,L}	Equianalgesic Doses (mg) ^{1,3,4}		Approximate Equianalgesic 24 hr Dose (Assumes Around-the-Clock Dosing) ⁵		Usual Starting Dose (Opioid-Naïve Adults) (Doses NOT Equianalgesic)	
	Parenteral	Oral	Parenteral	Oral/Other	Parenteral	Oral/Other
Codeine ⁿ	100-130	200	30-50 mg q 4 h	60 mg q 4 h	10 mg q 3-4 h ⁵²	15-60 mg q 4 h (mild to moderately severe pain) ⁴⁶ 15-30 mg q 4-12 h (chronic noncancer pain) ^{14,41}
Controlled-release codeine (<i>Codeine Contin</i> [Canada]) ^{m,n}	NA	200	NA	180 mg q 12 h	NA	50 mg q 12 h ⁴⁹
Methadone (<i>Dolophine</i> [U.S.], <i>Metadol</i> [Canada]) ^o	Variable	Variable	For opioid-tolerant patients only. ¹⁴ The conversion ratio of methadone is highly variable depending on factors such as patient tolerance, morphine dose, and length of dosing (short-term versus chronic dosing). Because the analgesic duration of action is shorter than the half-life, toxicity due to drug accumulation can occur with just a few doses. ³⁵ For conversion methods, see http://www.cancer.gov/cancertopics/pdq/supportivecare/pain/HealthProfessional/page3 . Some experts recommend that only those with substantial experience with its use should prescribe methadone. ^{39,55}			
Meperidine (<i>Demerol</i>)	75	300	Should be used for acute dosing only (short duration of action [2.5 to 3.5 hours]) and neurotoxic metabolite, normeperidine. ¹ Avoid in renal insufficiency and use caution in hepatic impairment and in the elderly (potential for toxicity due to accumulation of normeperidine). ^{1,16-18} Seizures, myoclonus, tremor, confusion, and delirium may occur. ¹			

Drug ^{f,i,k,L}	Equianalgesic Doses (mg) ^{1,3,4}		Approximate Equianalgesic 24 hr Dose (Assumes Around-the-Clock Dosing) ^g		Usual Starting Dose (Opioid-Naïve Adults) (Doses NOT Equianalgesic)	
	Parenteral	Oral	Parenteral	Oral/Other	Parenteral	Oral/Other
Fentanyl ^P	0.1	NA	All noninjectable fentanyl products are <u>for opioid-tolerant patients only</u> . Do <u>not</u> convert mcg for mcg among fentanyl products (i.e., patch, transmucosal lozenge [<i>Actiq</i> (U.S.)], buccal tablet [<i>Fentora</i> (U.S.)], buccal film [<i>Onsolis</i>], nasal spray [<i>Lazanda</i> (U.S.)], sublingual tablet [<i>Abstral</i>]). See specific product labeling (U.S.: Drugs@FDA; Canada: Health Canada Drug Product Database) for dosing. Or, for <u>U.S.</u> products only, see our <i>PL Chart, Fentanyl Products for Breakthrough Pain</i> . Some experts use this conversion in cancer patients: oral morphine 60 mg total daily dose = 25 mcg/hr fentanyl patch. Round up or down based on patient factors and available patch sizes. ⁵⁶			

NA = not available.

Most of the above oral opioids are available as generics. Exceptions (prices are AWP [U.S.]) include: *Kadian* (\$6.63/30 mg cap), *Avinza* (\$5.45/30 mg cap), *Opana* (\$6.53/10 mg tab), *Opana ER* (\$4.35/10 mg tab), *OxyContin* (\$2.43/10 mg tab), *Embeda* (\$4.98/20 mg cap), and *Exalgo* (\$8.99/8 mg). As a comparison, generic morphine controlled-release = \$1.69/30 mg tab.

- a. Product labeling for **hydromorphone** recommends a starting dose of 0.2 mg to 1 mg IV every two to three hours (Canadian labeling: 2 mg IV every four to six hours) as needed, or 2 mg to 4 mg orally every four to six hours as needed.^{8,15,20} An even lower oral starting dose (2 mg two or three times daily) has been recommended for chronic pain in opioid-naïve patients.¹⁴ Some institutions use even lower doses of parenteral hydromorphone (e.g., 0.2 mg to 0.5 mg every two hours as needed). One regimen starts opioid-naïve patients at 0.2 mg IV every two hours as needed for mild or moderate pain, with the option in moderate pain to give an extra 0.2 mg after 15 minutes if relief is inadequate after the first 0.2 mg dose. For severe pain, 0.5 mg IV every two hours as needed is used initially. In adults <65 years of age, the 0.5 mg dose can be repeated in 15 minutes if relief is inadequate, for a maximum of 1 mg in two hours.
- b. Per the product labeling, convert to **Exalgo** 12 mg *from* oral codeine 200 mg, hydrocodone 30 mg, morphine 60 mg, oxycodone 30 mg, oxymorphone 20 mg, or transdermal fentanyl 25 mcg/hr. After 50% dose reduction for incomplete cross-tolerance, reduce dose again by 50% for moderate renal impairment, and by 75% for severe renal or moderate hepatic impairment. Not for use in severe hepatic impairment.¹³ The **Jurnista** product monograph recommends a 5:1 oral morphine:oral hydromorphone conversion ratio.¹⁹
- c. Per the product labeling, oral **oxymorphone** 10 mg ER is approximately equivalent to hydrocodone 20 mg or oxycodone 20 mg.¹¹
- d. **Dilaudid** Canadian monograph recommends parenteral starting dose of 2 mg.²⁰ See footnote “a” for additional information and precautions.

- e. No initial dose for **Exalgo**. For opioid-tolerant patients only.¹³ Initial **Jurnista** dose (opioid-naïve or <40 mg daily oral morphine equivalents) is 4 to 8 mg q 24 h.¹⁹
- f. **Tramadol** (e.g., *Ultram*, *Ralivia* [Canada]), potency is about one-tenth that of morphine, similar to codeine.¹ The maximum daily dose of tramadol is 300 mg to 400 mg, depending on the product.^{22-28,36,37} See product labeling for dosing in elderly, or in renal or hepatic dysfunction.
- g. Examples of doses seen in clinical practice, taking into account available dosage strengths.
- h. Labeling for some products (*MS Contin* [U.S.], *Kadian*, *Jurnista* [Canada]) recommends beginning treatment with an immediate-release formulation.^{6,19,21,29}
- i. **Tapentadol** controlled-release (*Nucynta CR*, Canada) and oxycodone controlled-release exhibit comparable pain relief in a dose ratio of 5:1 (tapentadol:oxycodone).³¹ The maximum dose of tapentadol CR is 250 mg twice daily.³¹ No specific dose conversion is given for *Nucynta* (U.S.), *Nucynta IR* (Canada) and *Nucynta ER* (U.S.).^{32,33} Not for use in severe renal or hepatic dysfunction.^{31-33,38}
- j. Some experts do not recommend for chronic pain in opioid-naïve patients.¹⁴
- k. The initial dose of transdermal **buprenorphine** (*Butrans*) for patients taking less than 30 mg of oral morphine or equivalent per day is a 5 mcg/hr patch applied once weekly (Canada: start with 5 mcg/hr patch in opioid-naïve patients, and 5-10 mcg/hr patch in patients taking up to 80 mg oral morphine equivalents per day). U.S.: When converting from 30 to 80 mg of morphine equivalents daily dose, first taper to 30 mg oral morphine equivalents, then start with the 10 mcg/hr patch.³⁴ The maximum dose is 20 mcg/hr patch once weekly.^{34,47}
- L. Parenteral morphine 10 mg is approximately equal to parenteral **pentazocine** 60 mg, oral pentazocine 180 mg, parenteral **butorphanol** 2 mg, and parenteral **nalbuphine** 10 mg.⁴⁹ For buprenorphine transdermal patch (*Butrans*), see footnote “k.” The analgesic efficacy of these drugs is limited by a dose ceiling. Furthermore, the mixed agonists-antagonists (i.e., pentazocine, butorphanol, nalbuphine) are contraindicated for use in patients receiving an opioid agonist because they can precipitate withdrawal and increase pain. They also pose a risk of psychotomimetic effects.¹
- m. Reduce dose by 25% when switching from oral **codeine** phosphate to account for phosphate content of tablet.⁴⁹
- n. Analgesic efficacy limited by a dose ceiling.^{46,49}
- o. Relatively safe choice in renal or liver insufficiency.^{54,55}
- p. Relatively safe choice in renal or liver insufficiency.⁵⁵ Clearance reduced by uremia.⁵⁴ Do not start with patch in renal or liver failure.⁵⁴ Watch for delayed toxicity.^{54,55}
- q. *Opana ER* has received a notice of compliance (June 2012) by Health Canada. At time of publication, it is not yet available on the Canadian market.
- r. Start with an oral dose of 5 mg q 4-6 h for opioid-naïve elderly or opioid-naïve patients with renal or liver impairment.⁴⁴

Users of this PL Detail-Document are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical judgments based on the content of this document. Our editors have researched the information with input from experts, government agencies, and national organizations. Information and Internet links in this article were current as of the date of publication.

Project Leader in preparation of this PL Detail-Document: Melanie Cupp, Pharm.D., BCPS

References

1. National Cancer Institute Pain (PDQ). Pharmacologic management. <http://www.cancer.gov/cancertopics/pdq/supportivecare/pain/HealthProfessional/page3>. (Accessed July 13, 2012).
2. Pergolizzi J, Boger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). *Pain Pract* 2008;8:287-313.
3. Agency for Healthcare Research and Quality. Morbidity & mortality rounds on the web. Case & commentary. Strassels SA. Miscalculated risk. Hospital medicine. August 2006. <http://webmm.ahrq.gov/case.aspx?caseID=132#table1>. (Accessed July 13, 2012).
4. American Academy of Hospice and Palliative Medicine. Key principles of opioid administration. <http://www.aahpm.org/pdf/equianalgesictable.pdf>. (Accessed July 13, 2012).
5. American Academy of Hospice and Palliative Medicine. Guidelines for prescribing opiates for hospice and palliative care patients. <http://www.aahpm.org/pdf/guidelinesforopioids.pdf>. (Accessed July 16, 2012).
6. Product information for *Kadian*. Actavis Kadian LLC. Morristown, NJ 07960. July 2012.
7. Product information for *Avinza*. King Pharmaceuticals, Inc. Bristol, TN 37620. July 2012.
8. Product information for *Dilaudid* injection. Purdue Pharma L.P. Stamford, CT 06901. June 2011.
9. Argoff CE, Silvershein DI. A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs. *Mayo Clin Proc* 2009;84:602-12.
10. Product information for *Opana* injection. Endo Pharm. Chadds Ford, PA 19317. June 2006.
11. Product information for *Opana ER*. Endo Pharm. Chadds Ford, PA 19317. July 2012.
12. Product information for *Embeda*. King Pharmaceuticals, Inc. Bristol, TN 37620. July 2012.
13. Product information for *Exalgo*. Mallinckrodt Brand Pharmaceuticals, Inc.. July 2012.
14. Manchikanti L, Abdi A, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2-guidance. *Pain Physician* 2012;15:S67-S116.
15. Product information for *Dilaudid* oral liquid and tablets. Abbott Laboratories. North Chicago, IL 60064. November 2007.
16. Product information for *Demerol*. Sanofi-aventis U.S. Bridgewater, NJ 08807. October 2011.
17. Fulton CW. Limiting meperidine use in pain management. *Hosp Pharm* 2001;36:1214,1217-8.
18. *PL Detail-Document*, Pharmacotherapy Choices for Patients with Dementia. *Pharmacist's Letter/Prescriber's Letter*. May 2008.
19. Product monograph for *Jurnista*. Janssen-Ortho Inc. Toronto, ON M3C 1L9. May 2012.
20. Product monograph for *Dilaudid*. Purdue Pharma. Pickering, ON L1W 3W8. August 2008.
21. Product monograph for *Kadian*. Abbott Labs. Vaughan, ON L4K 4T7. December 2006.
22. Product information for *Ultram*. PriCara. Raritan, NJ 08869. September 2009.
23. Product information for *Ultracet*. PriCara. Raritan, NJ 08869. June 2011.
24. Product information for *Ultram ER*. PriCara. Raritan NJ 08869. June 2009.
25. Product monograph for *Ralivia*. Valeant Canada LP. Montreal, QC H4R 2P9. February 2011.
26. Product monograph for *Tramacet*. Janssen-Ortho Inc. Toronto, ON M3C 1L9. October 2011.
27. Product monograph for *Zytram XL*. Purdue Pharma. Pickering, ON L1W 3W8. December 2010.
28. Product monograph for *Tridural*. Labopharm Inc. Laval, QC H7V 4B4. July 2010.
29. Product information for *MS Contin*. Purdue Pharma, L.P. Stamford, CT 06901. July 2012.
30. Product monograph for *Hydromorph Contin*. Purdue Pharma. Pickering, ON L1W 3W8. November 2010.
31. Product monograph for *Nucynta CR*. Janssen. Toronto, ON M3C 1L9. May 2012.
32. Product information for *Nucynta ER*. Janssen. Titusville, NJ 08560. July 2012.
33. Product information for *Nucynta*. Janssen Pharmaceuticals, Inc. Titusville, NJ 08560. July 2011.
34. FDA. Introduction for the FDA blueprint for prescriber education for extended-release and long-acting opioid analgesics. July 9, 2012. <http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM277916.pdf>. (Accessed July 14, 2012).
35. *PL Detail Document*, Methadone: Focus on Safety. *Pharmacist's Letter/Prescriber's Letter*. September 2006.
36. Product monograph for *Durela*. Cipher Pharmaceuticals Inc. Mississauga, ON L4W 4P1. August 2011.
37. eCPS [Internet]. Ottawa (ON): Canadian Pharmacists Association c2012. *Ultram* monograph (October 2010). <http://www.e-therapeutics.ca>. (Accessed June 22, 2012).
38. Product monograph for *Nucynta IR*. Janssen Inc. Markham, ON L3R 0T5. January 2012.
39. Centers for Disease Control and Prevention (CDC). Vital signs: risk of overdose from methadone used for pain relief-United States, 1999-2010. *MMWR Morb Mortal Wkly Rep* 2012;61:493-7.
40. Prescribing information for morphine solution. Roxane Laboratories, Inc. Columbus, OH 43216. January 2012.

More . . .

41. Sundwall DN, Rolfs RT, Johnson E. Utah Department of Health. Utah clinical guidelines on prescribing opioids for treatment of pain. 2009. <http://www.dopl.utah.gov/licensing/forms/OpioidGuidlines.pdf>. (Accessed July 2012).
42. Product information for *Oxecta*. King Pharmaceuticals Inc. Bristol, TN 37620. June 2011.
43. Product monograph for *Oxy IR*. Purdue Pharma. Pickering, ON L1W 3W8. June 2012.
44. Product information for *Opana*. Endo Pharmaceuticals Inc. Chadds Ford, PA 19317. August 2011.
45. Product information for *Vicodin*. Abbott Laboratories. North Chicago, IL 60064. September 2011.
46. Product information for codeine sulfate tablets. Roxane Laboratories, Inc. Columbus, OH 43228. April 2012.
47. Product monograph for *BuTrans*. Purdue Pharma. Pickering, ON L1W 3W8. March 2012.
48. *PL Detail-Document*, Opioids for Chronic Non-cancer Pain. *Pharmacist's Letter/Prescriber's Letter*. September 2010.
49. Product monograph for *Codeine Contin*. Purdue Pharma. Pickering, ON L1W 3W8. November 2011.
50. eCPS [Internet]. Ottawa (ON): Canadian Pharmacists Association c2012. *Opioids* monograph (March 2012). <http://www.e-therapeutics.ca>. (Accessed July 16, 2012).
51. eCPS [Internet]. Ottawa (ON): Canadian Pharmacists Association c2012. *MS IR* monograph (April 2011). <http://www.e-therapeutics.ca>. (Accessed July 16, 2012).
52. Ballantyne JC, Mao J. Opioid therapy for chronic pain. *N Engl J Med* 2003;349:1943-53.
53. *PL Detail-Document*, Codeine Safety in Kids. *Pharmacist's Letter/Prescriber's Letter*. June 2012.
54. Induru RR, Lagman RL. Managing cancer pain: frequently asked questions. *Cleve Clin J Med* 2011;78:449-64.
55. Carbonara GM. Opioids in patients with renal or hepatic dysfunction. *Practical Pain Management*. May 1, 2008. <http://www.practicalpainmanagement.com/treatments/pharmacological/opioids/opioids-patients-renal-hepatic-dysfunction?page=0,0>. (Accessed July 18, 2012).
56. Skaer TL. Transdermal opioids for cancer pain. *Health Qual Life Outcomes* 2006;4:24.

Cite this document as follows: PL Detail-Document, Equianalgesic Dosing of Opioids for Pain Management. Pharmacist's Letter/Prescriber's Letter. August 2012.



Evidence and Recommendations You Can Trust...



3120 West March Lane, P.O. Box 8190, Stockton, CA 95208 ~ TEL (209) 472-2240 ~ FAX (209) 472-2249
Copyright © 2012 by Therapeutic Research Center

Subscribers to the *Letter* can get *PL Detail-Documents*, like this one, on any topic covered in any issue by going to www.pharmacistsletter.com, www.prescribersletter.com, or www.pharmacytechniciansletter.com